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Introduction
The biological response to a static magnetic field (SMF) has
recently been widely studied from the perspective of possible
health benefits as well as potential hazards (1–3). With respect
to the possible health effects, it has been reported that local
SMF application has beneficial actions in orthopedic diseases.
In Japan, SMF generated by small, cylindrical Ferrite mag-
nets has been used to provide pain relief from neck, shoulder
and lower back pain (4,5). These magnetotherapies have been
found to be clinically effective.
Rat adjuvant arthritis (AA) is a model of acute periarticular
proliferative synovitis that is induced by a single intradermal
injection of tubercle bacillus in the rat posterior foot (6). As one
of the experimental arthritis models, AA rats have been used
to evaluate the efficacy of drugs, especially anti-inflammatory
drugs, at several institutions (7). In the present study, AA rats
were left untreated for a prolonged period to develop chronic
pain and osteopenia models (8). These model animals were
exposed to SMF, and its influence on the tail surface tempera-
ture and the level of locomotor activity was assessed using a
thermograph and a metabolism measuring system, respectively.
The effect of the SMF on the bone mineral density (BMD) and
serum inflammatory markers was also studied.
Subjects and Methods
Study Animals and Environmental Conditions
Female Sprague–Dawley (SD) rats (age: 5 weeks, body
weight: approximately 150 g) were purchased from Japan Crea
Co., Ltd. (Shizuoka, Japan). The animals were housed individ-
ually in cages and kept in a room maintained at a temperature
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derivative work this must be clearly indicated.of 23.0   1.0 C with a relative humidity (RH) of 55   5% and
a 12 h/12 h light/dark cycle. Solid rodent chow and tap water
were offered ad libitum. After 1 week of acclimatization under
these conditions, animals showing favorable growth were
selected and used for further studies.
In addition, this research was approved by the animal
experiment Ethics Committee of this University. The animals
were sacrificed under anesthesia and the femur was extracted.
Experimental Animals
Sixty female SD rats (age: 6 weeks, body weight: approxi-
mately 160 g) were divided into three groups. In Group I (20
animals) and Group II (20 animals), Mycobacterium butyrium
suspended in paraffin oil (0.05 ml) was injected in the left
posterior foot in a dose of 0.6 mg/0.05 ml to induce AA. These
animals were then maintained for 24 weeks to develop a
chronic pain model. Starting at 24 weeks, Group I was exposed
to SMF for 12 weeks (up to week 36 after the onset of AA).
Group II (the non-SMF-treated AA rats) was not exposed to
SMF. The 20 normal rats in Group III (control rats) were main-
tained without any treatment for 36 weeks (Fig. 1).
Conditions of Exposure to SMF
The SMF exposure device (length, 300 mm; height, 130 mm;
width, 440 mm; Pip Fujimoto Co., Ltd., Osaka, Japan) was
composed of a pair of rectangular magnetic plates, externally
placed parallel to and at the shortest distance of 1 cm from
both the outer sides of a transparent cage (length, 340 mm;
height, 180 mm; width 400 mm) (Fig. 2A, B). The mean flux
density at the center of the cage was 30 mT (range, 20–80 mT)
and the magnetic surface was 200 mT (Fig. 2C).
For Group I, the SMF exposure device was fixed on the left
and right sides of the cage, and each animal was exposed to the
magnetic field continuously for 12 weeks. For Group II, a
0 mT magnetic surface was similarly placed as a control.
Measurement of Parameters
Measurement of Tail Surface Temperature
To avoid the influence of the haircoat, the tail surface temper-
ature was used as an indicator of the peripheral circulation (9).
The tail surface temperature was measured before and after 
12-week exposure to SMF (at 24 weeks and 36 weeks) in
Group I, and at the respective time points in Group II and
Group III. The tail surface temperature was measured using a
thermograph (TVS-2300 Mk IIST; Japan Abionics Co., Ltd.,
Tokyo, Japan). After 15-min acclimatization to the environ-
ment, the tail surface temperature was measured in conscious
animals in a windless room maintained at a temperature of
15   1 C with 50–55% RH. In thermography, the mean skin
temperature of the entire tail was determined using the soft-
ware for temperature measurement (TW-SIBMW, resolution:
0.01; Japan Abionics Co., Ltd., Tokyo, Japan).
Measurement of the Level of Locomotor Activity Over 24 h
The level of locomotor activity over a 24-h period was measured
before and after 12-week exposure to the SMF (at 24 weeks and
36 weeks) in Group I, and at the respective time points in Group
II and Group III. The level of locomotor activity was measured
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Figure 1. Schematic diagram of the magnet, showing its top (A) and front (B) plan view. The mean magnetic force at the center of the cage was 30 mT (C).using a metabolism measuring system (SCANET MV-10; Toyo
Sangyo Co., Ltd., Toyama, Japan). In this system, infrared rays
are spread horizontally (lengthwise and breadthwise) at 5-mm
intervals, and the number of infrared rays blocked by the animal
is counted at 30-s intervals (10). The total locomotor activity
over 24 h was measured as the daily locomotor activity.
Further, the magnitude of change in the locomotor activity was
calculated as the rate of increase in locomotor activity by the 
following equation: rate of increase in locomotor activity  
(locomotor activity after exposure—locomotor activity before
exposure)   (locomotor activity before exposure)   100.
Measurement of the Levels of Serum Inflammatory
Markers and Femoral BMD
Each animal was sacrificed under deep ether anesthesia. Blood
was drawn from the cervical vein, and the serum was isolated.
The level of albumin (Ab) and sialic acid were assayed using
commercial kits (Wako Pure Chemical Industries, Ltd.,
Wakayama, Japan). The level of acid-soluble glycoprotein
(ASGP) was assayed using a Sequential Multiple Autoanalyser
plus Computer (Technion, Ltd., Tokyo, Japan). Both femoral
bones were obtained and their BMD was measured by dual-
energy X-ray absorptiometry (DEXA; DCS-600R Dichroma
scan, Aloca Co., Ltd., Tokyo, Japan). The mean BMD of the
two femoral bones was calculated. The BMD of the entire
femoral bone was measured using the software for the analy-
sis of BMD (small animal mode, SYS-D 62-V 6.0; Aloca Co.,
Ltd., Tokyo, Japan).
Data Analyses
The data obtained in each group are expressed as the
mean   standard error. The significance of the differences
among groups was assessed by the Wilcoxon sum-rank test,
and the level of significance was set at P   0.05.
Results
Tail Surface Temperature Before and After 
Exposure to SMF
Before exposure of Group I to the SMF at 24 weeks, the tail
surface temperature was significantly lower in the AA rats
(Group I and Group II) than in the control rats (Group III).
After 12-week exposure of Group I to the SMF (at 36 weeks),
the tail surface temperature of the SMF-treated AA rats
(Group I) was significantly higher than that of the non-
SMF-treated AA rats (Group II). No significant difference was
observed in the tail surface temperature between Group I and
Group III at 36 weeks (Table 1).
Locomotor Activity Before and After Exposure to SMF
Before exposure of Group I to the SMF at 24 weeks, the level
of daily locomotor activity was lower in the AA rats (Group I
and Group II) than in the control rats (Group III) (Table 2).
After 12-week exposure of Group I to the SMF, the rate of
increase in locomotor activity was significantly higher in the
SMF-treated AA rats (Group I) than in the non-SMF-treated
AA rats (Group II).
Serum Ab, Sialic Acid,ASGP Levels and BMD After
Exposure to SMF
The serum Ab level was significantly lower in the AA rats
(Group I and Group II) than in the control rats (Group III). 
A significant difference was observed in the ASGP levels
between the SMF-treated AA rats (Group I) and the non-SMF-
treated AA rats (Group II) (Table 3).
The BMD was significantly lower in the non-SMF-treated
AA rats (Group II) than in the control rats (Group III).
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Figure 2. The level of locomotor activity was measured using a
metabolism measuring system (SCANET MV-10; Toyo Sangyo
Co., Ltd., Toyama, Japan). In this system, infrared rays are
spread horizontally (lengthwise and breadthwise) at 5-mm inter-
vals, and the number of infrared rays blocked by the animal is
counted at 30-s intervals. The total locomotor activity over 24 h
was measured as the daily locomotor activity.However, there was a significant difference between the SMF
treated AA rats (Group I) and the control rats (Group III).
Discussion
AA has been widely studied and is used as a model of experi-
mental arthropathy in the evaluation of drugs, especially,
anti-inflammatory agents (11). The mechanism involved in the
development of rat AA is autoimmunity cross-reaction, in
which T lymphoids sensitized to tubercle bacillus cross-react
with a protein in rat articular cartilages, causing arthritis (12).
However, the pathology of this model may not be the same as
that of human rheumatic arthritis, although similar symptoms
develop in both (13). Briefly, although the redness and swell-
ing in various joints worsen 2–3 weeks after the induction of
AA, these symptoms resolve subsequently, leaving articular
ankylosing deformity. Histologically, both chronic granuloma-
tous inflammation and acute inflammation associated with
inflammatory cell infiltration have been noted in rat AA, and
the disease does not reach the chronic state (14).
We maintained AA rats without treatment for a prolonged
period to utilize the animals as chronic ischemic pain and
osteopenia models. Rheumatic arthritis is often accompanied
by ankylosing deformity and coldness of the joints, and it is
thought that AA rats that have not been treated for a prolonged
period can be used as an experimental model of abnormal cold
feeling (15).
Several factors, including systemic changes due to the pain of
multiple arthritis, side effects caused by treatments such as
steroid preparations and osteoporosis due to a reduction in phys-
ical activity, are considered to contribute to the onset of osteope-
nia accompanied by rheumatic arthritis. In particular, reduced
physical activity is said to cause reductions in the BMD of the
lumbar and femoral bones. In fact, we have previously con-
firmed by computed X-ray densitometry (CXD) and DEXA that
AA rats that have been kept untreated over a prolonged period
can be used as an experimental osteopenia model.
In the present study, animals that had remained untreated
for 6 months after the induction of AA were exposed to SMF.
Since the tail surface temperature of AA animals significantly
increased by an average of 1.43 C after prolonged exposure
to SMF for 12 weeks, it is suggested that exposure to SMF
improved the peripheral circulation. The mechanism of SMF
action may be as follows: it was previously shown that exposure
to a magnetic force increased the release of acetylcholine from
cholinergic vasodilator nerve endings by inhibiting the effect
of cholinesterase, resulting in vasodilation (16). Further, it was
confirmed using a metabolism measuring system that the loco-
motor activity of AA rats was clearly higher (approximately
10% increase in a 24-h period) after 12 weeks of exposure to
SMF than before the exposure. Furthermore, there was a signi-
ficant difference in the observed levels of serum inflammatory
markers (ASGP) between the SMF-treated and non-SMF-
treated AA rats. Therefore, SMF appeared to have an analgesic
action; a clinical study reported that SMF therapy relieved pain
in patients with neck and shoulder pain and muscle fatigue
due to ischemic conditions in the microcirculation (17). We have
previously reported that the tail skin temperature as well as the
activity of AA rats treated with moxibustion increased signifi-
cantly compared with normal rats. Moxibustion has been
widely employed for relieving the perception of pain (18).
Consequently, the SMF-induced increase in locomotor activ-
ity in our AA rats was presumably ascribable to the alleviation
of pain rather than to the induction of stress. Physical therapy,
including therapeutic exercise of bones, has been reported
to be very effective for osteoporosis (19). Briefly, since the
dynamic exercise of bones is considered to improve the bone
structure and increase BMD, physical therapy is generally
preferable to drug therapy, which may cause side effects. In
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Table 1. Tail surface temperature of AA and normal rats before and after 
12- week exposure to SMF
Tail surface temperature ( C)
Before After
Group I: SMF-treated AA rats 14.63   0.26*** 16.06   0.26#
Group II: Non-treated AA rats 15.18   0.17*** 15.17   0.30*
Group III: Control rats 16.14   0.19 16.34   0.46
Group II and Group III were not exposed to SMF. The results are expressed
as mean   SEM. *P   0.05; significantly different between before and after
in Group I, #P   0.05; ***P   0.001.
Table 2. Locomotor activity over a 24-h period of AA and normal rats
before and after 12 week exposure to SMF
Locomotor Activity (count)
Before After
Group I: SMF-treated AA rats 68983   9090*,*** 78279   8902*,**
Group II: Non-treated AA rats 71745   8683*** 72340   9807***
Group III: Control rats 133358   10132 145263   7773
Group II and Group III were not exposed to SMF. The results are expressed
as mean   SEM. *P   0.05; ***P   0.001.
Table 3. Serum inflammatory markers and BMD in AA and control rats after 12-week exposure to SMF
Changes in inflammatory index substances and BMD
Albumin (g/dl) Sialic acid (mg/dl) ASGP (mg/dl) BMD (g/cm2)
Group I: SMF-treated AA rats 4.52   0.13** 124.3   23.6 275.5   1.9* 192.6   4.2*
Group II: Non-treated AA rats 4.17   0.18** 134.9   16.3 281.2   2.8* 179.5   3.2*,**
Group III: Control rats 5.15   0.03 110.9   8.4 262.5   1.9 195.5   3.3**
The results are expressed as mean   SEM. *P   0.05; **P   0.01.Japanese individuals, it was confirmed by the quantitative ultra-
sound method that the BMD among people who habitually
exercised was significantly higher than that among people who
consumed a large quantity of nutritional food, but did not
exercise (20). These results suggest that the increased BMD of
AA animals upon exposure to SMF was partially ascribable to
the increased locomotor activity. It was reported that 3 weeks
after the implantation of a 200-mT magnet into the femoral
bone in a rat osteoporosis model that had been prepared by
ligating the femoral artery, there was an approximately 10%
increase in the BMD, as recorded by DEXA (21).
Therefore, the possibility that SMF directly affects the bone
cannot be ruled out, because the BMD also increased with the
increase in locomotor activity.
Further basic research using a pathophysiological animal
model is necessary to clarify the pain relieving mechanism
of SMF in various painful conditions, e.g., ischemic and
inflammatory pain.
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